LONDON - Shares in Genmab A/S reached a record high of DKK267 (US$45) after the Danish antibody company unveiled a stripped-down antibody construct, Unibody, and outlined progress in the development of the clinical portfolio at an R&D update meeting held here last week. (BioWorld International) Read More
